Artificial Intelligence–Enhanced Risk Stratification of Cancer Therapeutics–Related Cardiac Dysfunction Using Electrocardiographic Images
AI applied to baseline ECG images can stratify the risk of early CTRCD associated with anthracycline or trastuzumab exposure in the setting of breast cancer and non-Hodgkin lymphoma therapy.
Authors
- Lauren A. Baldassarre (ORCID: https://orcid.org/0000-0003-4173-3449)
- Rohan Khera (ORCID: https://orcid.org/0000-0001-9467-6199)
- Lovedeep Singh Dhingra (ORCID: https://orcid.org/0000-0002-5664-4126)
- Arya Aminorroaya (ORCID: https://orcid.org/0000-0003-3197-2657)
- Veer Sangha (ORCID: https://orcid.org/0000-0002-8524-1203)
- Andreas Coppi (ORCID: https://orcid.org/0000-0002-5243-552X)
- Harlan M. Krumholz (ORCID: https://orcid.org/0000-0003-2046-127X)
- Evangelos K. Oikonomou (ORCID: https://orcid.org/0000-0003-4362-0720)
Institutions
- Yale New Haven Hospital (US)
- Yale University (US)
- University of Oxford (GB)
- Yale New Haven Health System (US)
- Science Oxford (GB)
Publication Details
- Journal
- Circulation Cardiovascular Quality and Outcomes
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1161/circoutcomes.124.011504
- Citations
- 41
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 16.08
Funders
- Bristol-Myers Squibb
- Yale University
- Shenzhen Center for Health Information
- University of Oxford
- Novo Nordisk
- National Institutes of Health
- Centers for Medicare and Medicaid Services
- National Heart, Lung, and Blood Institute